AU2009267145A1 - Solid dosage formulations of telcagepant potassium - Google Patents

Solid dosage formulations of telcagepant potassium Download PDF

Info

Publication number
AU2009267145A1
AU2009267145A1 AU2009267145A AU2009267145A AU2009267145A1 AU 2009267145 A1 AU2009267145 A1 AU 2009267145A1 AU 2009267145 A AU2009267145 A AU 2009267145A AU 2009267145 A AU2009267145 A AU 2009267145A AU 2009267145 A1 AU2009267145 A1 AU 2009267145A1
Authority
AU
Australia
Prior art keywords
oxo
solid dosage
pharmaceutical formulation
dihydro
azepan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009267145A
Other languages
English (en)
Inventor
Majid Mahjour
Aaron J. Moment
Dan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2009267145A1 publication Critical patent/AU2009267145A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2009267145A 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium Abandoned AU2009267145A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13354208P 2008-06-30 2008-06-30
US61/133,542 2008-06-30
PCT/US2009/049009 WO2010002763A1 (en) 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium

Publications (1)

Publication Number Publication Date
AU2009267145A1 true AU2009267145A1 (en) 2010-01-07

Family

ID=41057505

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009267145A Abandoned AU2009267145A1 (en) 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium

Country Status (16)

Country Link
US (1) US20100009967A1 (https=)
EP (1) EP2303238A1 (https=)
JP (2) JP2011526909A (https=)
KR (1) KR20110025926A (https=)
CN (1) CN102076330A (https=)
AR (1) AR072395A1 (https=)
AU (1) AU2009267145A1 (https=)
CA (1) CA2728547A1 (https=)
CR (1) CR20110038A (https=)
DO (1) DOP2010000409A (https=)
IL (1) IL209833A0 (https=)
MX (1) MX2010014524A (https=)
RU (1) RU2011103170A (https=)
SV (1) SV2010003774A (https=)
TW (1) TW201004954A (https=)
WO (1) WO2010002763A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125979B2 (en) * 2007-10-25 2015-09-08 Proteus Digital Health, Inc. Fluid transfer port information system
AU2009212514A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Prodrugs of CGRP receptor antagonist
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
WO1998040069A2 (en) * 1997-03-13 1998-09-17 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
AU2007238896A1 (en) * 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. CGRP antagonist salt
EP2063708A2 (en) * 2006-09-08 2009-06-03 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Also Published As

Publication number Publication date
RU2011103170A (ru) 2012-08-10
CA2728547A1 (en) 2010-01-07
US20100009967A1 (en) 2010-01-14
TW201004954A (en) 2010-02-01
EP2303238A1 (en) 2011-04-06
CN102076330A (zh) 2011-05-25
AR072395A1 (es) 2010-08-25
MX2010014524A (es) 2011-02-24
SV2010003774A (es) 2011-03-23
CR20110038A (es) 2011-03-16
IL209833A0 (en) 2011-02-28
KR20110025926A (ko) 2011-03-14
DOP2010000409A (es) 2011-02-15
JP2011246478A (ja) 2011-12-08
WO2010002763A1 (en) 2010-01-07
JP2011526909A (ja) 2011-10-20

Similar Documents

Publication Publication Date Title
KR100738861B1 (ko) 베타-카르볼린 약학 조성물
KR101612146B1 (ko) 도파민 수용체 리간드를 함유하는 약학적 제형
AU773666B2 (en) Beta-carboline drug products
RS60731B1 (sr) Čvrsti oblici jedinjenja koje modulira kinaze
SK86695A3 (en) Anticonvulsive agents for treatment of parkinson`s disease and parkinsonian syndromes
RU2716595C2 (ru) Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения
CN101406470A (zh) 吡啶杂环衍生物的用途及含其的药物组合物
AU2015215044A1 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
KR101630467B1 (ko) 진통 내성 억제제
CA3154915A1 (en) New formulations
AU2009267145A1 (en) Solid dosage formulations of telcagepant potassium
US20040058914A1 (en) Combination drugs
US10085991B2 (en) Formulation inhibiting effects of low acid environment
US20040023951A1 (en) Combination therapy for treatment of psychoses
KR20120099215A (ko) 다운 증후군을 치료하기 위한 방법 및 약학적 조성물
JP2004502655A (ja) 精神病の処置のための組み合わせ療法
EP4346773B1 (en) A plurality of tasquinimod particles and use thereof
US20050090537A1 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
AU2011224697A1 (en) Arylvinylazacycloalkane compounds for constipation
HK40107035B (en) A plurality of tasquinimod particles and use thereof
HK40107035A (en) A plurality of tasquinimod particles and use thereof
JP2025525407A (ja) エルラグルシブの経口剤形
WO2022076709A1 (en) Formulation of a pan-jak inhibitor
CA3176718A1 (en) Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
HK40004728A (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period